









Diacerhein attenuates the inflammatory response
and improves survival in a model of severe sepsis
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Abstract
Introduction: Hyperglycemia and insulin resistance have been associated with a worse outcome in sepsis.
Although tight glycemic control through insulin therapy has been shown to reduce morbidity and mortality rates,
the effect of intensive insulin therapy in patients with severe sepsis is controversial because of the increased risk of
serious adverse events related to hypoglycemia. Recently, knowledge about diacerhein, an anthraquinone drug
with powerful antiinflammatory properties, revealed that this drug improves insulin sensitivity, mediated by the
reversal of chronic subclinical inflammation. The aim of the present study was to evaluate whether the
antiinflammatory effects of diacerhein after onset of sepsis-induced glycemic alterations is beneficial and whether
the survival rate is prolonged in this situation.
Methods: Diffuse sepsis was induced by cecal ligation and puncture surgery (CLP) in male Wistar rats. Blood
glucose and inflammatory cytokine levels were assessed 24 hours after CLP. The effect of diacerhein on survival of
septic animals was investigated in parallel with insulin signaling and its modulators in liver, muscle, and adipose
tissue.
Results: Here we demonstrated that diacerhein treatment improves survival during peritoneal-induced sepsis and
inhibits sepsis-induced insulin resistance by improving insulin signaling via increased insulin-receptor substrate-1-
associated phosphatidylinositol 3-kinase activity and Akt phosphorylation. Diacerhein also decreases the activation
of endoplasmic reticulum stress signaling that involves upregulation of proinflammatory pathways, such as the I
kappa B kinase and c-Jun NH2-terminal kinase, which blunts insulin-induced insulin signaling in liver, muscle, and
adipose tissue. Additionally, our data show that this drug promoted downregulation of proinflammatory signaling
cascades that culminate in transcription of immunomodulatory factors such interleukin (IL)-1b, IL-6, and tumor
necrosis factor-a.
Conclusions: This study demonstrated that diacerhein treatment increases survival and attenuates the
inflammatory response with a significant effect on insulin sensitivity. On the basis of efficacy and safety profile,
diacerhein represents a novel antiinflammatory therapy for management of insulin resistance in sepsis and a
potential approach for future clinical trials.
Introduction
Sepsis is defined as a systemic inflammatory response
syndrome caused by the body’s response to an infection
[1]. During the onset of sepsis, the inflammatory system
becomes hyperactive, leading to a production of proin-
flammatory molecules and cytokine release [2], which
contribute to septic shock, multiple organ failure, and
death. Hyperglycemia and insulin resistance occur as a
consequence of the metabolic effects of stress hormones
and the overproduction of proinflammatory mediators in
sepsis [3,4]. In this regard, tissue insulin resistance may
be used as an important indicator of the resultant actions
of the proinflammatory cytokines, being a tissue marker
of the severity of sepsis before organ failure. In addition,
this hyperglycemia may lead to inflammatory stress [5,6]
and aggravate sepsis, as previously described [7,8].
Both bacterial components such as lipopolysaccharide
(LPS), and proinflammatory cytokines such as interleukin
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(IL)-1b, IL-6, and tumor necrosis factor (TNF)-a, result-
ing from the immune response to sepsis, may activate
intracellular mechanisms associated with insulin resis-
tance, such as the IKKb/NF-B, and JNK pathways. JNK
has been shown to promote insulin resistance through
serine phosphorylation of IRS-1, preventing signaling
from the insulin receptor. Furthermore, IKKb induces
insulin resistance through activation of NF-B, which in
turn induces the transcription of several genes related to
proinflammatory cytokine release (IL-1b, TNF-a, IL-6,
and IL-8) [9]. IKK activation leads to phosphorylation,
ubiquitination, and degradation of IB, which releases
NF-B, allowing it to translocate to the nucleus and acti-
vate transcription of target genes [10].
In this regard, we believe that the evaluation of insulin
signaling pathways through PI3K/Akt in liver, muscle,
and adipose tissue may be important indicators of this
overreaction at the tissue level, and the improvement in
this signaling pathway, induced by some treatments, in
parallel with a decrease in tissue inflammation, may pre-
dict the effectiveness of this treatment. Substantial
resources have been invested in developing and evaluat-
ing potential therapies for sepsis and in increasing
knowledge of systemic inflammation and multiple-sys-
tem organ failure [11,12], although pharmacologic inter-
ventions available now are not effective in decreasing
the high mortality rates.
Diacerhein (4,5-diacetoxy-9,10-dihydro-9,10-dioco-2-
anthracenecarboxylic acid) is an anthraquinone that
shows antiinflammatory properties, in addition to mod-
erate analgesic and antipyretic characteristics [11], and
is used in the treatment of osteoarthritis. Clinical studies
have suggested that diacerhein can exert beneficial
effects on the symptoms of osteoarthritis, including anti-
arthritic and chondroprotective effects [13]. Rhein, the
active metabolite of diacerhein, has been demonstrated
to inhibit the synthesis and activity of proinflammatory
cytokines such as TNF-a, IL-6, and IL-1b [14-17]. The
compound also acts directly on inflammatory cells, inhi-
biting superoxide anion production by human neutro-
phils, release of lysosomal enzymes, chemotaxis, and
phagocytic activity of neutrophils and macrophages
[18-22].
Further studies have suggested that diacerhein inhibits
nitric oxide production induced by the reduction of IL-
1b [23,24]. Besides its inhibitory effects on proinflamma-
tory genes, rhein has been shown to have antitumor
activity on several cancer cell lines [25,26]. Moreover,
studies suggest that diacerhein and rhein inhibit NF-B
activation and expression of NF-B-dependent genes
[24]. In this regard, diacerhein has the potential to
improve insulin resistance in sepsis and to reduce the
overreaction of the inflammatory response, without
inducing hypoglycemia.
The aim of the present study was to investigate
whether diacerhein, by reducing tissue activation of
inflammatory pathways, can improve insulin signaling
and survival in sepsis.
Materials and methods
Anti-IR-b (a-IR), anti-IRS-1, anti-Akt, anti-caspase-3
anti-p-IR, anti-p-IRS-1, anti-p-IKKb, anti-p-IBa, anti-
NF-B, anti-p-JNK, anti-JNK1, anti-p-PERK, and anti-
IRE1 antibodies were obtained from Santa Cruz Tech-
nology (Santa Cruz, CA, USA). Anti-p-Akt was from
Cell Signaling Technology (Beverly, MA, USA). Anti-p-
IRS-1ser307 was obtained from Upstate Biotechnology,
Inc. (Lake Placid, NY, USA). Anti-p-eIF2a was from
Abcam (Cambridge, MA, USA). Diacerhein was kindly
provided by TRB-Pharma (Campinas, Brazil). Human
recombinant insulin was from Eli Lilly and Co. (Indiana-
polis, IN, USA). Routine reagents were purchased from
Sigma Chemical Co. (St. Louis, MO, USA), unless other-
wise specified.
Animal care and experimental procedures
All experiments were approved by the Ethics Committee
at the University of Campinas, CEEA/Unicamp 1267-1.
Male Wistar Hannover rats (8 weeks old) were maintained
in a room with 12-hour day/night cycles and room tem-
perature of 21°C, with food and water ad libitum.
Polymicrobial sepsis was induced by subjecting rats to
CLP, as previously described [27], and is a commonly
used surgical technique in rodents and thought to be a
clinically relevant animal model of sepsis. Anesthesia
was induced by i.p. administration of ketamine (80 mg/
kg BW) and xylazine (15 mg/kg). Through a 1-cm
abdominal midline incision, the cecum was ligated
below the ileocecal valve, with careful attention to avoid
obstruction of the ileum or colon. The cecum was sub-
jected to four ‘’through-and through’’ perforations (20-
gauge needle). The abdominal incision was closed in
layers. Sham-operated rats underwent the same proce-
dure, except for ligation and perforation of the cecum.
All procedures were performed under sterile conditions.
Wistar rats were randomly divided into four groups; dia-
cerhein-treated sepsis (Sepsis/Dia), vehicle-treated sepsis
(Sepsis/Veh), diacerhein-treated sham (Sham), and vehi-
cle-treated sham (Control).
Diacerhein-administration protocol
Dried diacerhein was diluted in 0.01 M PBS 3% DMSO,
to a final concentration of 18 mg/ml. Three hours after
the induction of sepsis and every 24 hours, rats received
diacerhein (100 mg/kg/day) or an equivalent volume of
vehicle by oral gavage.
Preliminary experiments using lower doses of diacer-
hein (10 and 20 mg/kg/day) showed no beneficial effects
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on survival curves, nor even on insulin sensitivity in sep-
tic animals. The chosen dose (100 mg/kg/day) was based
on a previous study [28]. This dose is safe and lower
than the LD50 for rats (980 mg/kg). The only adverse
effect observed was softening of fecal contents, given the
anthraquinone nature of diacerhein. The oral route of
administration is indicated for this drug, which is
promptly deacetylated to rhein, its active metabolite,
soon after its administration.
Sepsis-survival studies
For survival studies, Wistar rats (n = 15 per group) were
induced to sepsis, allowed to recover, and then treated
with diacerhein (100 mg/kg/day) or placebo 3 hours
after surgery and then once per day, and were then
observed twice per day. To avoid interference, these ani-
mals were not submitted to any other experimental pro-
cedures. The overall difference in survival rate was
determined with the Kaplan-Meier test followed by a
log-rank test.
Homeostasis model assessment
To perform the Insulin Tolerance Test (ITT), a group
of overnight-fasted rats (n = 8 per group) were treated
with diacerhein or vehicle only once, 3 hours after sep-
sis or sham surgery. Insulin (1.5 U/kg) was adminis-
tered by i.p. injection at 24 hours after surgery, and
blood samples were collected at 0, 5, 10, 15, 20, 25, and
30 minutes. Blood glucose was measured by the glucose
oxidase method (Optium Xceed; Abbott, Libertyville,
IL, USA) as previously described [29]. The constant
rate for glucose disappearance (Kitt) was calculated
by using the formula 0.693/t1/2. Glucose t1/2 was calcu-
lated from the slope of the least-squares analysis of
plasma glucose concentrations during the linear decay
phase [30].
Tissue extraction and immunoblotting
To perform the tissue analysis 24 hours after CLP or
sham surgery, other groups (n = 8 per group) were
used, and the animals were treated with diacerhein or
vehicle 3 hours after CLP and were then anesthetized
with intraperitoneal injection of sodium thiopental and
were used 10 to 15 minutes later (that is, as soon as
anesthesia was assured by the loss of pedal and corneal
reflexes). Five minutes after saline (0.2 ml) or insulin
injection (3.8 U/kg i.p.), liver, muscle, and adipose tissue
were removed, minced coarsely, and homogenized
immediately in extraction buffer, as described elsewhere.
NF-B p50 activation was determined in nuclear
extracts from liver, muscle, and adipose tissue. The
whole-tissue extracts were subjected to SDS-PAGE and
immunoblotting, as previously described [31].
ELISA assays
Blood was collected 24 hours after CLP or sham surgery
from other groups (n = 8 per group), and IL-1b, IL-6,
TNF-a and NF-B were determined by using commer-
cially available ELISA kits (Pierce Biotechnology Inc.,
Rockford, IL, USA), following the instructions of the
manufacturer.
Statistical analysis
Specific protein bands presented in the blots were quanti-
fied with digital densitometry (ScionCorp Inc., Frederick,
MD, USA). Means ± SEMs obtained from densitometric
scans, area measurements, and the values for blood cyto-
kines and glucose were compared with ANOVA with
post hoc test (Bonferroni). A value of P < 0.05 was
accepted as statistically significant.
Results
Diacerhein improves survival in septic rats
To test the hypothesis that diacerhein decreases sepsis
mortality, we monitored the survival in animals in
which sepsis was induced via CLP. Diacerhein (100 mg/
kg/day) or placebo was administered by gavage 3 hours
after surgery and in sham-operated animals. No deaths
occurred in the sham-operated animals, whether or not
they had been treated with diacerhein. The survival
curves showed a significantly improved survival (P <
0.0001) after diacerhein treatment (Figure 1A).
As shown in Figure 2A, septic animals were more
insulin resistant than sham-operated rats, fasting plasma
glucose was higher in septic rats than in the control
group, and diacerhein treatment reduced both of these
levels. As depicted in Figure 2B, the plasma glucose dis-
appearance rates measured during the insulin tolerance
test (Kitt), were lower in septic animals, and diacerhein
treatment attenuated this alteration. Diacerhein treat-
ment had no effect on glucose tolerance in the sham
group. Taken together, these data suggest that diacer-
hein improves sepsis-induced insulin resistance.
Effect of diacerhein on serum levels of IL-1b, IL-6, and
TNF-a
IL-1b, IL-6, and TNF-a serum levels were examined in
the four groups studied. As expected, cytokine levels in
the septic rats were higher than in the sham-operated
rats. After diacerhein treatment, a significant decrease
was found in IL-1b (Figure 3A), IL-6 (Figure 3B), and
TNF-a (Figure 3C) circulating levels.
Diacerhein improves insulin signaling in septic animals
We then examined the effects of diacerhein administra-
tion on the insulin signaling pathway in its main target
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tissues. In the sepsis group, insulin-induced IR and IRS-
1 tyrosine phosphorylation were decreased in liver, mus-
cle, and adipose tissue when compared with those in
sham rats, and these alterations were attenuated by dia-
cerhein (Figure 4A to 4C). Also, a decrease was found
in insulin-induced Akt serine phosphorylation in liver,
muscle, and adipose tissue of septic animals when com-
pared with sham rats, and diacerhein was able to
increase Akt phosphorylation (Figure 4A to 4C). The
modulation in IR, IRS-1 and Akt phosphorylation
induced by sepsis was independent of changes in tissue
protein expression (Figure 4A to 4C). The protein con-
centrations of IR, IRS-1, and Akt did not change among
the groups. Equal protein loading in the gels was con-
firmed by repeated probing of the membranes with an
anti-b-actin antibody (lower panels).
Diacerhein attenuates sepsis-induced inflammatory
changes
During sepsis, the activation of proinflammatory signal-
ing involves upregulation of intracellular inflammatory
pathways, such as the IKKb and the JNK pathways. We
examined the antiinflammatory effects of diacerhein on
the IKK/NF-B pathway by monitoring the main func-
tion of IKK phosphorylation and degradation of the NF-
B inhibitor (IBa) [32]. NF-B was monitored through
Figure 1 Effect of diacerhein on survival in CLP sepsis model. (A) Male Wistar rats, 8 weeks old, were given vehicle (Sepsis/Veh (■), n = 15)
or diacerhein, 100 mg/kg (Sepsis/Dia (◆), n = 15), 3 hours and once a day after CLP. Survival of the rats was monitored at intervals of 12 hours
for 15 days. The overall difference in survival rate between the groups with and without diacerhein was significant (P < 0.05).
Figure 2 Fasting blood glucose (A) and glucose disappearance rate (B). Data are presented as mean and SD of six to eight rats per group.
*P < 0.05 versus Sham/Vehicle; #P < 0.05 (Sepsis/Veh versus Sepsis/Dia). C, Sham/Vehicle; ShD, Sham/Diacerhein; VEH, Sepsis/Vehicle; DIA, Sepsis/
Diacerhein.
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analysis of NF-B p65 nuclear expression. As expected,
IKKb and IB phosphorylation were increased in liver,
muscle and adipose tissue of septic animals. When trea-
ted with diacerhein, septic rats showed a reduction in
IKKb and IB phosphorylation in all tissues studied
(Figure 5A through C). Likewise, we assessed the
nuclear translocation of NF-B p65 and, as expected, in
nuclear tissue extracts from treated septic rats, we
detected reduced expression of NF-B p65 compared
with the nontreated group (Figure 5A through C).
JNK activation was determined by monitoring phos-
phorylation of JNK1 and total expression of this protein.
JNK phosphorylation in liver, muscle, and adipose tissue
was increased in septic animals, and diacerhein induced
a downmodulation in the phosphorylation of this serine
kinase in liver and adipose tissue (Figure 6A through C).
We also investigated Ser307 phosphorylation of IRS-1 in
the three tissues from the four groups of rats. Ser307
phosphorylation was induced by sepsis, and the diacer-
hein treatment attenuated this alteration (Figure 6A
through C).
Previous studies showed that sepsis is also character-
ized by endoplasmic reticulum (ER) stress. It is clear
that ER stress can also induce activation of JNK and
IKKb. We therefore investigated the effect of sepsis
(treated or nontreated with diacerhein) on proteins that
reflect ER stress. Our data showed that sepsis induced
ER stress, with activation of the membrane kinase PERK
(PKR-like endoplasmic reticulum kinase) and its sub-
strate eIF2a (eukaryotic translation initiation factor 2a),
and increased the expression of IRE1 (Figure 7A
through C). Treatment with diacerhein significantly
reduced the activation of IRE1, PERK, and its substrate
eIF2a (Figure 7A through C). Also, we measured cas-
pase 3, a critical effector molecule of cell death, and
observed that diacerhein inhibited caspase 3 activation
in liver and adipose tissue (Figure 7A through C).
Discussion
In the present study, we demonstrated that administra-
tion of the antiinflammatory diacerhein improved survival
during peritoneal-induced sepsis, with a significant effect
Figure 3 Serum levels of IL-6 (A), IL-6 (B), and TNF-a (C). Data are presented as mean and SD of six to eight rats per group. *P < 0.05 versus
Sham/Vehicle; #P < 0.05 (Sepsis/Veh versus Sepsis/Dia). C, Sham/Vehicle; ShD, Sham/Diacerhein; VEH, Sepsis/Vehicle; DIA, Sepsis/Diacerhein.
Representative blots show total and insulin-induced protein expression.
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Figure 4 Effects of diacerhein treatment on insulin signaling in the CLP rat. Representative blots show total protein expression and insulin-
induced tyrosine phosphorylation of IRb, IRS1, and serine phosphorylation of Akt in liver (A), adipose tissue (B), and muscle (C) of sham and
septic rats. Data are presented as mean ± SEM from six to eight rats per group. *P < 0.05 versus Sham/Vehicle; #P < 0.05 (Sepsis/Veh versus
Sepsis/Dia). IB, immunoblot; Sham, Sham/Vehicle; Sham+Dia, Sham/Diacerhein; Sepsis, Sepsis/Vehicle; Sepsis+Dia: Sepsis/Diacerhein.
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Figure 5 Effects of diacerhein treatment on the IKK/NF-B pathway signaling in the CLP rat. Representative blots show the IKKb, IB
phosphorylation, and protein expression of NF-B in liver (A), adipose tissue (B), and muscle (C) of sham and septic rats. Blots were stripped
and reprobed with b-actin (lower panels) to confirm equal loading of proteins. Data are presented as mean ± SEM from six to eight rats per
group. *P < 0.05 versus Sham/Vehicle; #P < 0.05 (Sepsis/Veh versus Sepsis/Dia). IB, immunoblot; Sham, Sham/Vehicle; Sham+Dia, Sham/
Diacerhein; Sepsis, Sepsis/Vehicle; Sepsis+Dia, Sepsis/Diacerhein.
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Figure 6 Effects of diacerhein treatment on the JNK pathway signaling in the CLP rat. Representative blots show the JNK phosphorylation,
total protein expression of JNK, and serine 307 phosphorylation of IRS1 in liver (A), adipose tissue (B), and muscle (C) of sham and septic rats.
Blots were stripped and reprobed with b-actin (lower panels) to confirm equal loading of proteins. Data are presented as mean ± SEM from six
to eight rats per group. *P < 0.05 versus Sham/Vehicle; #P < 0.05 (Sepsis/Veh versus Sepsis/Dia). IB, immunoblot; Sham, Sham/Vehicle; Sham+Dia,
Sham/Diacerhein; Sepsis, Sepsis/Vehicle; Sepsis+Dia, Sepsis/Diacerhein.
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on insulin sensitivity. In addition, this drug promoted
downregulation of proinflammatory signaling cascades
that culminate in the transcription of immunomodulatory
factors such as interleukins and TNF-a. Our data show
that diacerhein is able to attenuate increased levels of IL-
1b, IL-6, and TNF-a, and reduce insulin resistance, as
demonstrated by the insulin tolerance test. The improve-
ment in insulin sensitivity was probably due to the
increased IRS-1-associated PI3-kinase activity and Akt
phosphorylation.
Figure 7 Effects of diacerhein treatment on proteins that reflect ER stress in the CLP rat. Representative blots show the PERK, eIF2a
phosphorylation, and IRE-1 expression in liver (A), adipose tissue (B), and muscle (C) of sham and septic rats. Blots were stripped and reprobed
with b-actin (lower panels) to confirm equal loading of proteins. Data are presented as mean ± SEM from six to eight rats per group. *P < 0.05
versus Sham/Vehicle; #P < 0.05 (Sepsis/Veh versus Sepsis/Dia). IB, immunoblot; Sham, Sham/Vehicle; Sham+Dia, Sham/Diacerhein; Sepsis, Sepsis/
Vehicle; Sepsis+Dia, Sepsis/Diacerhein.
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In recent years, studies have shown a direct link
between metabolic and immune signaling systems in dif-
ferent conditions of insulin resistance [9,33-35]. We and
others previously demonstrated that activation of
inflammatory signaling through IKKb and JNK is trig-
gered in metabolic disorders and that this activation cul-
minates in an increase in proinflammatory gene
expression, which may play critical roles in insulin resis-
tance [31,35,36].
Our data show that diacerhein decreases activation of
the IKK/IB/NF-B pathway, a modulation that may
play a role in the attenuated expression of inflammatory
mediators in response to a septic insult. IKK pathway
activation increases serine phosphorylation of IR and
IRS-1, inducing insulin resistance [37,38]. It has also
been proposed that increased IKK activity can inhibit
insulin-stimulated PI3-kinase activity [39]. In this
respect, the capacity of insulin to stimulate PI3-kinase
activity and Akt phosphorylation was highly improved
in septic animals treated with diacerhein.
Enhanced NF-B activation is associated with a poorer
outcome in sepsis [40-42]. NF-B nuclear translocation
induces transcription of IL-1b, IL-6, and TNF-a [32,43].
The picture of hyperglycemia and insulin resistance
observed in sepsis, often referred to as “stress diabetes,”
reflects the activation of signaling pathways and hyper-
expression of inflammatory mediators that inhibit insu-
lin action [44]. In this regard, the inhibition of NF-B
activation explains the reduced serum levels of TNF-a,
IL-1b, and IL-6 in diacerhein-treated animals and, con-
sequently, the improvement in the sepsis-induced insu-
lin-resistance process.
Another mechanism involved in the host response to
sepsis is activation of the proinflammatory JNK pathway.
Several studies suggest that JNK contributes to insulin
resistance. Our data show that diacerhein inhibits JNK
phosphorylation in septic rats and indicate that the ben-
eficial effects of this drug in improving survival and
reducing insulin resistance are mediated by different
pathways. Because many inflammatory pathways are
triggered in sepsis, merely blocking a single component
is likely to be insufficient to halt the process [45,46].
Indeed, therapies modulating entire families of media-
tors seem to be more efficacious [45,47].
Here we observed that sepsis led to serine phosphory-
lation of IRS-1, and diacerhein reduced this phenom-
enon in three insulin-target tissues. Thus, negative
modulators of the intracellular cascade triggered by
insulin, such as JNK and IKK, are partly responsible for
the establishment of insulin resistance and represent
potential therapeutic targets for sepsis-induced insulin
resistance.
One mechanism that, based on newly emerging data,
appears to have a central role in the activation of
inflammatory pathways is endoplasmic reticulum (ER)
stress [48]. If ER stress continues for a certain period,
then programmed cell death is triggered. This response
has a close relation to sepsis, because sepsis generates
conditions that increase demands on the ER. In the pre-
sent study, we showed that diacerhein strongly inhibited
phosphorylation of PERK and its substrate eIF2a, as
well as IRE1a expression, suggesting that this drug can
attenuate ER stress induced by sepsis.
ER stress plays a central role in the activation of
inflammatory signaling. In both in vitro and in vivo stu-
dies, ER stress leads to activation of JNK and thus con-
tributes to insulin resistance [49-51]. Interestingly, ER
stress also activates IKK, and thus may represent a com-
mon mechanism for the activation of these two impor-
tant signaling pathways [52]. Acute inflammation,
oxidative stress, and ER stress seem to contribute to the
association of sepsis with insulin resistance. The phar-
macologic attenuation of all the aforementioned stresses
leads to improved insulin sensitivity and consequently
to favorable sepsis outcomes.
An initial investigation by Van den Berghe and collea-
gues [53] suggested that controlling blood glucose levels
by intensive insulin therapy decreased mortality and
morbidity after surgery on critically ill patients. More-
over, intensive insulin therapy halved the prevalence of
bloodstream infections and prolonged inflammation,
showing the antiinflammatory action of insulin. These
findings were supported by further studies demonstrat-
ing that insulin has antiinflammatory effects via activa-
tion of the PI3K-Akt pathway [54,55]. In addition,
insulin has potent acute antiinflammatory effects,
including reductions in intranuclear NF-B [56] and
several key mediators of oxidative stress [57].
It is important to mention that the reduced inflamma-
tory response induced by diacerhein probably played a
central role in improving insulin signaling, but the
improvement in this pathway may also have a role in the
improved survival. It is possible that reduced insulin sig-
naling through the IRSs/PI3K/Akt pathways in sepsis may
contribute to multiorgan failure by activation of apoptosis
[58]. Additionally, studies have shown that prevention of
apoptosis may be a potential treatment for sepsis in
humans [59-61]. Diacerhein, by improving insulin-induced
PI3K and Akt, may play a critical role in protection from
apoptosis in sepsis. In accordance with this, our data
showed that caspase 3, which was increased in tissues of
septic animals, decreased after diacerhein treatment.
Growing evidence suggests that the PI3K/Akt pathway
plays an important role as a negative regulator of innate
immune response by counteracting excessive production
of proinflammatory mediators. The PI3K-Akt pathway
has been shown to regulate negatively NF-B and the
expression of inflammatory genes [62-64]. Inhibition of
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the PI3K-Akt pathway enhances LPS-induced TNF-a
and TF gene expression [55], and activates the mitogen-
activated protein kinase pathways (ERK1/2, p38, and
JNK) as well as the downstream target AP-1 [54]. Also
relevant in this regard is a report showing that PI3K-
knockout mice fail to respond to LPS [65]. In this con-
text, it is possible that restoration of this pathway,
induced by diacerhein, may contribute to the antiinflam-
matory effect of this drug.
Conversely, the role of intensive insulin therapy in
patients with severe sepsis is uncertain, because the ben-
eficial effects of insulin may be overcome by the
increased risk of serious adverse events related to hypo-
glycemia [66]. We propose that drugs capable of rever-
sing sepsis-induced insulin resistance, in the context of
maintenance of adequate glycemic control, may be a
potential therapy for sepsis. In this regard, diacerhein
may be a potential therapeutic strategy for sepsis, with a
significant effect on insulin sensitivity and insulin signal-
ing in peripheral tissues.
Our data show that administration of the antiinflam-
matory diacerhein in septic animals increased survival,
with significant effects on insulin sensitivity and insulin
signaling in peripheral tissues. The treatment also
reduced NF-B activation, in association with upstream
JNK and IKK activation, decreased serum levels of cyto-
kines, and improved ER stress. Our results indicate that
diacerhein treatment attenuates insulin resistance in
sepsis, and in parallel modulates inflammatory pathways.
Conclusions
This is the first report demonstrating that diacerhein
improves survival and insulin signaling, which is blunted
in sepsis, and in parallel, attenuates the inflammatory
response. On the basis of its efficacy, safety profile, and
rare side effects, this drug may be an alternative therapy
for management of insulin resistance in sepsis.
Key messages
• Hyperglycemia and insulin resistance have been
associated with poorer outcomes in sepsis, and tight
glycemic control through insulin therapy has been
shown to reduce morbidity and mortality rates.
• However, insulin-induced hypoglycemia may coun-
teract the beneficial effects of aggressive insulin ther-
apy in patients with severe sepsis.
• These data suggest that the ideal drug to improve
survival in sepsis should reduce overreaction by the
inflammatory response and, in parallel, should
improve the insulin signaling pathway, without indu-
cing hypoglycemia.
• Diacerhein improved survival during peritoneal-
induced sepsis, with a significant effect on insulin sensi-
tivity. In addition, this drug promoted downregulation
of proinflammatory signaling cascades, which culmi-
nate in the transcription of immunomodulatory factors
such as interleukins and TNF-a.
• The effect of diacerhein on suppression of the
inflammatory response may play a central role in the
regulation of insulin signaling and survival in septic
insult. Diacerhein may represent a potential new
approach to sepsis treatment.
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polyacrylamide gel; ShD: sham/diacerhein; TNF-α: tumor necrosis factor-α;
UPR: unfolded protein response; Veh: vehicle.
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